- Report
- February 2023
- 50 Pages
Global
From €3541EUR$3,950USD£3,068GBP
- Report
- April 2025
- 85 Pages
Saudi Arabia
From €3137EUR$3,500USD£2,718GBP
- Report
- February 2025
- 185 Pages
Global
From €4034EUR$4,500USD£3,495GBP
- Report
- January 2025
- 133 Pages
Europe
From €3586EUR$4,000USD£3,107GBP
- Report
- January 2025
- 82 Pages
Vietnam
From €3137EUR$3,500USD£2,718GBP
- Report
- December 2024
- 85 Pages
Spain
From €3137EUR$3,500USD£2,718GBP
- Report
- September 2024
- 80 Pages
Japan
From €3137EUR$3,500USD£2,718GBP
- Report
- September 2024
- 80 Pages
France
From €3137EUR$3,500USD£2,718GBP
- Report
- August 2024
- 80 Pages
Japan
From €3137EUR$3,500USD£2,718GBP
- Report
- April 2024
- 185 Pages
Global
From €4034EUR$4,500USD£3,495GBP
- Report
- October 2023
- 133 Pages
Europe
From €3586EUR$4,000USD£3,107GBP
- Report
- October 2023
- 138 Pages
Asia Pacific
From €3586EUR$4,000USD£3,107GBP
From €3137EUR$3,500USD£2,718GBP
- Report
- March 2024
- 200 Pages
Global
From €3720EUR$4,150USD£3,223GBP
- Report
- January 2026
- 70 Pages
Indonesia
From €4258EUR$4,750USD£3,689GBP
- Report
- May 2025
- 70 Pages
Japan
From €4258EUR$4,750USD£3,689GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4258EUR$4,750USD£3,689GBP
- Report
- July 2024
- 70 Pages
Global
From €4258EUR$4,750USD£3,689GBP
- Report
- July 2024
- 70 Pages
Global
From €4258EUR$4,750USD£3,689GBP
- Report
- February 2024
- 150 Pages
Global
From €4258EUR$4,750USD£3,689GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more